Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Reexamination Certificate
2006-04-04
2006-04-04
Wilson, James O. (Department: 1623)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
C514S043000, C514S045000, C514S046000, C514S047000, C514S048000, C514S049000, C514S050000, C514S051000, C514S052000, C536S022100, C536S026100, C536S026200, C536S026210, C536S026240, C536S027100, C536S028100
Reexamination Certificate
active
07022680
ABSTRACT:
The present invention provides compounds having the formula:wherein A is a nitrogen-, oxygen-, or sulfur-linked aryl, alkyl, cyclic, or heterocyclic group, the group being further substituted with an electron contributing moiety; B is hydrogen, or a halogen, amino, or thiol group; C is hydrogen, or a halogen, amino, or thiol group; and D is a primary alcohol, a hydrogen, or an oxygen, nitrogen, carbon, or sulfur linked to phosphate, a phosphoryl group, a pyrophosphoryl group, or adenosine monophosphate through a phosphodiester or carbon-, nitrogen-, or sulfur-substituted phosphodiester bridge, or to adenosine diphosphate through a phosphodiester or carbon-, nitrogen-, or sulfur-substituted pyrophosphodiester bridge.The present invention also provides pharmaceutical compositions containing the above compounds, methods of using the above compounds as pharmaceuticals, and processes for preparing the above compounds.Also provided are methods for inhibiting an ADP-ribosyl transferase, ADP-ribosyl cyclase, ADP-ribosyl hydrolase, or NAD-dependent deacetylase enzyme, and methods for treating a disease or condition associated with an ADP-ribosyl transferase, ADP-ribosyl cyclase, ADP-ribosyl hydrolase, or NAD-dependent deacetylase enzyme in a subject in need of treatment thereof.
REFERENCES:
patent: 5569650 (1996-10-01), Watanabe et al.
patent: 5679394 (1997-10-01), Long, Jr. et al.
patent: 6103701 (2000-08-01), von Borstel et al.
patent: 2002/0132783 (2002-09-01), Sauve et al.
Sauve et al., “A Covalent Intermediate in CD38 is Responsible for ADP-Ribosylation and Cyclization Reactions”, J. of the American Chemical Society, vol. 122, No. 33, Aug. 23, 2000.
Sauve et al., J. Am. Chem. Soc., Vol. 122, pp. 7855-7859, 2000.
Ashamu et al., Roles for adenosine ribose hydroxyl groups in cyclic adenosine 5'-diphosphate ribose-mediated Ca2+ release. Biochemistry, 36:9509-9517, 1997.
Bailey et al., Cyclic aristeromycin diphosphate ribose: a potent and poorly hydrolysable Ca2+-mobilising mimic of cyclic adenosine diphoshate ribose. FEBS Lett., 379:227-230, 1996.
Berthelier et al., Human CD38 is an authentic NAD(P)+ glycohydrolase. Biochem J., 330:1383-1390, 1998.
Clapper et al., Pyridine nucleotide metabolities stimulate calcium release from sea urchin egg microsomes desensitized to inositol trisphoshate. J. Biol. Chem., 262:9561-9568, 1987.
Cockayne et al. Mice deficient for the ecto-nicotinamide adenine dinucleotide glycohydrolase CD38 exhibit altered humoral immune responses. Blood, 92:1324-1333, 1998.
Fernandez et al., Analysis of the distribution of human CD38 and of its ligand CD31 in normal tissues. J. Biol. Regul. Homeostatic Agents, 12:81-91, 1998.
Fox et al., Nucleosides. XII. Direct synthesis of 2'-deoxycytidine and its alpha-anomer. J. Am. Chem. Soc., 83:4066-4070, 1961.
Galione et al., Ca2+-induced Ca2+ release in sea urchin egg homogenates: modulation by cyclic ADP-ribose. Science, 253:1143-1146, 1991.
Handlon, and Oppenheimer, Substituent effects on the pH-independent hydrolysis of 2'-substituted nicotinamide arabinosides. J. Org. Chem., 56:5009-5010, 1991.
Hara-Yokoyama et al., Complex gangliosides as cell surface inhibitors for the Ecto-NAD+ glycohydrolase of CD38. Biochemistry, 40:888-895, 2001.
Howard et al., Formation and hydrolysis of cyclic ADP-ribose catalyzed by lymphocyte antigen CD38. Science, 262:1056-1059, 1993.
Itoh et al., Molecular cloning of murine BST-1 having homology with CD38 and Aplysia ADP-ribosyl cyclase. Biochem. Biophys. Res. Commun., 203:1309-1317, 1994.
Jackson and Bell, Isolation of a cDNA encoding the human CD38 (T10) molecule, a cell surface glycoprotein with an unusual discontinuous pattern of expression during lymphocyte differentiation. J. Immunol., 144:2811-2815, 1990.
Jiang et al., Membrane-permeant esters of phosphatidylinositol 3,4,5-trisphosphate. J. Biol. Chem., 273:11017-11024, 1998.
Kaisho et al., BST-1, a surface molecule of bone marrow stromal cell lines that facilitates pre-B-cell growth. Proc. Natl. Acad. Sci. USA, 91:5325-5329, 1994.
Kang et al., Synthesis and biological activity of bis(pivaloyloxymethyl) ester of 2'-azido-2'-deoxyuridine 5'-monophosphate. Nucleosides & Nucleotides, 17:1089-1098, 1998.
Kato et al., Regulatory role of CD38 (ADP-ribosyl cyclase/cyclic ADP-ribose hydrolase) in insulin secretion by glucose in pancreatic beta-cells. J. Biol. Chem., 270:30045-30050, 1995.
Khoo and Chang, Localization of plasma membrane CD38 is domain specific in rat hepatocyte. Arch. Biochem. Biophys., 373:35-43, 2000.
Kruppa et al., Bioactivatable derivatives of 8-substituted cAMP-analogues. Bioorg. Med. Chem. Lett., 7:945-948, 1997.
Lee, Modulator and messenger functions of cyclic ADP-ribose in calcium signaling. Recent Prog. Horm. Res., 51:355-388, 1996.
Lee, Physiological functions of cyclic ADP-ribose and NAAADP as calcium messengers. Annu. Rev. Pharmacol. Toxicol., 41:317-345, 2001.
Lee and Aarhus, ADP-ribosyl cyclase: an enzyme that cyclizes NAD+ into a calcium-mobilizing metabolite. Cell Regul., 2:203-209, 1991.
Lee and Aarhus, Fluorescent analogs of NAADP with calcium mobilizing activity. Biochim. Biophys. Acta., 1425:263-271, 1998.
Lee and Levitt, The crystal structure of cyclic ADP-ribose. Nature Struct. Biol., 1:143-144, 1994.
Li et al., Membrane-permeant esters of inositol polyshosphates, chemical syntheses and biological applications. Tetrahedron, 53:12017-12040, 1997.
Mehta et al., Human CD38, a cell-surface protein with multiple functions. FASEB J., 10:1408-1417, 1996.
Merkler et al., The rate constant describing slow-onset inhibition of yeast AMP deaminase by coformycin analogues is independent on inhibitor structure. Biochemistry, 29:8358-8364, 1990.
Mizuguchi et al., Neuronal localization of CD38 antigen in the human brain. Brain Res., 697:235-240, 1995.
Muller-Steffner et al., Slow-binding inhibition of NAD+ glycohydrolase by arabino analogues of beta-NAD. J. Biol. Chem., 267:9606-9611, 1992.
Munshi et al., Characterization of the active site of ADP-ribosyl cyclase. J. Biol. Chem., 274:30770-30777, 1999.
Normark et al., How neutrophils recognize bacteria and move toward infection. Nat. Med., 7:1182-1184, 2001.
Okamoto, The CD38-cyclic ADP-ribose signaling system in insulin secretion. Mol. Cell. Biochem., 193:115-118, 1999.
Oppenhemer and Handlon, Mechanism of NAD-dependent enzymes. In The Enzymes, Sigman, D.L. Ed., Academic Press Inc: San Diego CA, Chapter 10, vol. 20, pp 453-505, 1992.
Partida-Sanchez et al., Cyclic ADP-ribose production by CD38 regulates intracellular calcium release, extracellular calcium influx and chemotaxis in neutrophils and is required for bacterial clearance in vivo. Nat. Med., 7:1209-1216, 2001.
Porter et al., Identification of the active site nucleophile in nucleoside 2-deoxyribosyltransferase as glutamic acid 98. J. Biol. Chem., 270:15551-15556, 1995.
Reyes-Harde et al. Evidence of a role for cyclic ADP-ribose in long-term synaptic depression in hippocampus. Proc. Natl. Acad. Sci. USA, 96:4061-4066, 1999.
Rusinko and Lee, Widespread occurrence in animal tissues of an enzyme catalyzing the conversion of NAD+ into a cyclic metabolite with intracellular Ca2+-mobilizing activity. J. Biol. Chem., 264:11725-11731, 1989.
Sato et al., Inhibitor peptide SNP-1 binds to a soluble form of BST-1/CD157 at a 2:2 stoichiometry. Eur J Biochem, 264:439-445, 1999.
Sato et al., Novel peptide inhibitor of ecto-ADP-ribosyl cyclase of bone marrow stromal cell antigen-1 (BST-1/CD157). Biochem. J., 337:491-496, 1999.
Sauve et al., The reaction mechanism for CD38. A single intermediate is responsible for cyclization, hydrolysis, and base-exchange chemistries. Biochemistry, 37:13239-13249, 1998.
Sauve et al., A covalent intermediate in CD38 is responsible for ADP-ribosylation and cyclization reactions. J. Am. Chem. Soc., 122:7855-7859, 2000.
Sethi et al., 7-Deaza-8-bromo-cyclic ADP-ribose, the first membrane-permeant, hydrolysis-resistant cyclic ADP-ribose antagonist. J. Biol. Chem., 272:16358-16363, 1997.
Sleath et al., Pyridine coenzyme analogues. 3. Synthesis of three NAD+ analogues containing a 2'-d
Sauvé Anthony A.
Schramm Vern L.
Albert Einstein College of Medicine of Yeshiva University
Amster Rothstein & Ebenstein LLP
McIntosh III Traviss C.
Wilson James O.
LandOfFree
Inhibitors of ADP-ribosyl transferases, cyclases, and... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Inhibitors of ADP-ribosyl transferases, cyclases, and..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Inhibitors of ADP-ribosyl transferases, cyclases, and... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3527609